Horizon Discoveries, a biotech spin-out from Cambridge University, has announced the close of a £18.2m ($29.1m) series C round. The round was led by Dr Jonathan Milner, chief executive of life science firm Abcam. New investors in Horizon include the University of Cambridge Enterprise Fund, investment fund Wren Capital and venture firm Calculus Capital. Joining…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
